Cornerstone Therapeutics Inc. , a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration alleging that its Deconsal CT chewable tablets and Deconsal DM chewable tablets are new drugs lacking an approved application and as such should not be introduced into interstate commerce.

No associated text to display

Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.

Biotechnology company Antigenics Inc. said Friday it will not seek approval for a potential kidney cancer treatment after a European advisory committee recommended against approving the drug candidate.

Drug stocks cling to the flat line in morning activity while shares of Inovio Biomedical soar on positive clinical data for its new DNA-based flu vaccine.

Biotech drug developer Novavax Inc. said Friday it plans to offer 6.8 million of its shares in an underwritten public offering, at a price of $3.30 per share.

Flu drug developer BioCryst Pharmaceuticals Inc. priced its 5 million common stock share offering at $9.75 per share. On Thursday after the markets closed the company estimated gross proceeds of $48.8 million.

67 WALL STREET, New York - November 20, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available via The Wall Street Transcript Online.

Novavax, Inc. today announced that it has priced an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $3.30 per share.

Dendreon Corporation today announced that the U.S. Food and Drug Administration provided written acknowledgement that the Company's amended Biologics License Application for PROVENGE® is a complete response.

LONDON----Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has formally adopted a negative opinion on the marketing authorization application for Oncophage as a treatment in earlier-stage, localized renal cell carcinoma .

BERKELEY HEIGHTS, N.J.----Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® Injection, administered for the first time as a 1-hour high-dose intravenous infusion.

SAN DIEGO----Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta.

Novavax, Inc. today announced that it intends to offer shares of its common stock in an underwritten public offering.

CAMBRIDGE, Mass. & VANCOUVER, British Columbia----CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that the U.S.

No associated text to display

No associated text to display

SAN DIEGO----Inovio Biomedical Corporation , a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.

Cell Therapeutics, Inc. announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that CTI should be allowed to pursue all of its claims against The Lash Group, sending the case back to the District Court for trial.

No associated text to display